for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Innovate Biopharmaceuticals Inc

INNT.OQ

Latest Trade

--

Change

--(--)

Today's Range

--

 - 

--

52 Week Range

--

 - 

--

As of on the NASDAQ ∙ Minimum 15 minute delay

Latest Developments

Rdd Pharma To Acquire Naia Rare Diseases

Nov 13 (Reuters) - Innovate Biopharmaceuticals Inc <INNT.O>::RDD PHARMA ENTERS INTO NON-BINDING LETTER OF INTENT TO ACQUIRE NAIA RARE DISEASES, STRENGTHENING GASTROENTEROLOGY ORPHAN DISEASE PIPELINE.RDD PHARMA - CLOSING OF TRANSACTION ANTICIPATED TO OCCUR AFTER CONSUMMATION OF PROPOSED MERGER OF RDD, INNOVATE BIOPHARMACEUTICALS.RDD PHARMA - NAIA WILL RECEIVE CASH AND SHARES IN 9 METERS BIOPHARMA SUBJECT TO CLOSING OF INNT MERGER.RDD PHARMA - CORPORATE HEADQUARTERS FOR COMBINED COMPANY WILL BE LOCATED IN RALEIGH, NORTH CAROLINA.

Innovate Biopharmaceuticals To Acquire RDD

Oct 7 (Reuters) - Innovate Biopharmaceuticals Inc <INNT.O>::INNOVATE BIOPHARMACEUTICALS INC - TO ACQUIRE PRIVATELY-HELD RDD IN EXCHANGE FOR A COMBINATION OF COMMON & PREFERRED SHARES.INNOVATE BIOPHARMACEUTICALS - INNOVATE STOCKHOLDERS WILL OWN UP TO ABOUT 58.5% OF COMBINED CO & RDD STOCKHOLDERS WILL OWN AT LEAST 41.5%.INNOVATE BIOPHARMACEUTICALS - WILL BE RENAMED 9 METERS BIOPHARMA, INC. AND IS EXPECTED TO CONTINUE TO TRADE ON THE NASDAQ CAPITAL MARKET..INNOVATE BIOPHARMACEUTICALS - TEMPERATO WILL BECOME CEO AND JOIN THE BOARD OF 9 METERS BIOPHARMA.INNOVATE - ACTUAL STOCK ALLOCATION IS SUBJECT TO ADJUSTMENT BASED ON FINAL CAPITAL INVESTED OF UP TO $25 MILLION WITH INITIAL TRANCHE OF $10 MILLION.INNOVATE - TO BUY RDD IN EXCHANGE FOR NEWLY ISSUED SHARES REPRESENTING ABOUT 19.5% OF VOTING POWER AND SHARES OF CONVERTIBLE PREFERRED STOCK.

Innovate Biopharmaceuticals Q2 Loss Per Share $0.13

Aug 8 (Reuters) - Innovate Biopharmaceuticals Inc <INNT.O>::INNOVATE BIOPHARMACEUTICALS REPORTS SECOND QUARTER 2019 RESULTS AND CORPORATE UPDATES.Q2 LOSS PER SHARE $0.13.

Innovate Biopharmaceuticals Appoints Ed Sitar as Chief Financial Officer

June 24 (Reuters) - Innovate Biopharmaceuticals Inc <INNT.O>::INNOVATE BIOPHARMACEUTICALS EXPANDS ITS MANAGEMENT TEAM WITH THE ADDITION OF ED SITAR AS ITS CHIEF FINANCIAL OFFICER.INNOVATE BIOPHARMACEUTICALS INC - ANNOUNCED APPOINTMENT OF ED SITAR AS ITS CHIEF FINANCIAL OFFICER COMMENCING ON JULY 1, 2019.

Innovate Biopharmaceuticals Announces $8.7 Million Registered Direct Offering Priced At-The-Market

Innovate Biopharmaceuticals Inc <INNT.O>::INNOVATE BIOPHARMACEUTICALS ANNOUNCES $8.7 MILLION REGISTERED DIRECT OFFERING PRICED AT-THE-MARKET.INNOVATE BIOPHARMACEUTICALS INC - INTENDS TO USE PROCEEDS FOR PHASE 3 REGISTRATION TRIALS OF ITS LEAD PROGRAM, INN-202, OTHERS.INNOVATE BIOPHARMACEUTICALS INC - SALE OF 4.3 MILLION SHARES OF COMMON STOCK AT A PURCHASE PRICE OF $2.025 PER SHARE.INNOVATE BIOPHARMA - WILL ALSO ISSUE UNREGISTERED WARRANTS TO PURCHASE UP TO 4.3 MILLION SHARES OF COMMON STOCK WITH AN EXERCISE PRICE OF $2.13 PER SHARE..INNOVATE BIOPHARMA - WARRANTS WILL BE EXERCISABLE IMMEDIATELY FOLLOWING ISSUANCE AND WILL EXPIRE FIVE AND ONE-HALF YEARS FROM DATE OF ISSUANCE.

Innovate Biopharmaceuticals Reports Financing To Initiate The First Phase 3 Clinical Trial In Celiac Disease

March 19 (Reuters) - Innovate Biopharmaceuticals Inc <INNT.O>::INNOVATE BIOPHARMACEUTICALS REPORTS FINANCING TO INITIATE THE FIRST PHASE 3 CLINICAL TRIAL IN CELIAC DISEASE, FISCAL YEAR 2018 EARNINGS AND KEY CORPORATE HIGHLIGHTS.INNOVATE BIOPHARMACEUTICALS INC - CONTINUED LAUNCH ACTIVITIES FOR START OF FIRST PHASE 3 CELIAC DISEASE TRIAL, EXPECTED TO START Q2 2019.INNOVATE BIOPHARMACEUTICALS INC - INNOVATE CLOSES AN EQUITY FINANCING WITH GROSS PROCEEDS OF $9.7 MILLION.INNOVATE BIOPHARMACEUTICALS - AT DECEMBER 31, 2018, HAD $5.7 MILLION IN CASH AND CASH EQUIVALENTS COMPARED TO $0.4 MILLION AT DECEMBER 31, 2017..INNOVATE BIOPHARMA - TO USE NET PROCEEDS TO INITIATE ITS FIRST PHASE 3 REGISTRATION TRIAL OF LARAZOTIDE ACETATE, OR INN-202, FOR CELIAC DISEASE.

Innovate Biopharmaceuticals Announces Entry Into Securities Purchase Agreement To Fund Initiation Of The First Phase 3 Celiac Disease Clinical Trial

March 18 (Reuters) - Innovate Biopharmaceuticals Inc <INNT.O>::INNOVATE BIOPHARMACEUTICALS ANNOUNCES ENTRY INTO SECURITIES PURCHASE AGREEMENT TO FUND INITIATION OF THE FIRST PHASE 3 CELIAC DISEASE CLINICAL TRIAL.INNOVATE BIOPHARMACEUTICALS INC - OFFERING AT A PURCHASE PRICE OF $2.33 PER SHARE OF UP TO 4.3 MILLION SHARES, SOME WARRANTS.INNOVATE BIOPHARMACEUTICALS - INTENDS TO USE PROCEEDS FROM OFFERING TO FUND INITIATION OF FIRST PHASE 3 CLINICAL TRIAL OF FOR CELIAC DISEASE, INN-202.

Innovate Biopharmaceuticals Announces New CEO

Feb 22 (Reuters) - Innovate Biopharmaceuticals Inc <INNT.O>::INNOVATE BIOPHARMACEUTICALS ANNOUNCES A NEW CHIEF EXECUTIVE OFFICER AND CHIEF MEDICAL OFFICER.SANDEEP LAUMAS APPOINTED CEO.DEPARTURE OF CHIEF EXECUTIVE OFFICER AND MEMBER OF BOARD OF DIRECTORS, CHRISTOPHER PRIOR.LAUMAS SERVED AS EXECUTIVE CHAIRMAN OF INNOVATE BIOPHARMACEUTICALS INC. SINCE 2014.PATRICK GRIFFIN, M.D., FACP, APPOINTED AS CHIEF MEDICAL OFFICER.

Innovate Biopharmaceuticals Inc - Christopher Prior Resigned As Chief Executive Officer And As A Director, Effective Feb 19, 2019 - SEC Filing

Feb 19 (Reuters) - Innovate Biopharmaceuticals Inc <INNT.O>::INNOVATE BIOPHARMACEUTICALS INC - CHRISTOPHER P. PRIOR RESIGNED AS CHIEF EXECUTIVE OFFICER AND AS A DIRECTOR, EFFECTIVE FEB 19, 2019 - SEC FILING.INNOVATE BIOPHARMACEUTICALS INC - BOARD APPOINTED CURRENT EXECUTIVE CHAIRMAN, SANDEEP LAUMAS TO THE POSITION OF CHIEF EXECUTIVE OFFICER.

Innovate Biopharmaceuticals-Received Letter & Draft Complaint Regarding Co's Former Consultant Who Was Paid-Up In Cash & Stock For His Services

Dec 26 (Reuters) - Innovate Biopharmaceuticals Inc <INNT.O>::INNOVATE BIOPHARMACEUTICALS - RECEIVED LETTER & DRAFT COMPLAINT REGARDING CO'S FORMER CONSULTANT WHO WAS PAID-UP IN CASH & STOCK FOR HIS SERVICES.INNOVATE BIOPHARMACEUTICALS - COMPLAINT RELATED TO CONSULTANT DEMANDING DAMAGES OF UP TO ABOUT $3.6 MILLION PLUS PUNITIVE DAMAGES IN CONNECTION WITH A DELAY IN SUCH CONSULTANT’S ABILITY AND TIMING TO EXERCISE OPTIONS AND SELL SHARES OF THE COMPANY’S COMMON STOCK RELATED TO PAST CONSULTING SERVICES.

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up